Biomarker discovery and serum profiling

Biomarker discovery and serum profiling

Auto-antibodies in blood serum are useful resources when diagnosing autoimmune disorders and infectious diseases.  The recent advancement of immune checkpoint inhibitors as cancer therapies has given further importance to screening auto-antibodies as a method of monitoring treatment.

More recently, circulating tumour DNA (ctDNA) has shown promise as a biomarker in liquid biopsy, reducing the need for more invasive tumour biopsies.

Microarray spotterCDI Laboratories (Baltimore) utilise a Marathon Ultra II to manufacture HuProt, the world's largest human proteome array

To understand how HuProt can help with your proteome screening research, click here to email HuProt Project Manager, Saloni Sonawala


Selected publications

Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach
Jianbo Pan, Guang Song, Dunyan Chen, Yadong Li, Shuang Liu, Shaohui Hu, Christian Rosa, Daniel J. Eichinger, Ignacio Pino, Heng Zhu, Jiang Qian and Yi Huang
Molecular and Cellular Proteomics

Multiplexed biomarker panels discriminate Zika and Dengue virus infection in humans
Guang Song, Hee-Sool Rho, Jianbo Pan, Pedro Ramos, Ki-Jun Yoon, Freddy A. Medina, Emily M. Lee, Daniel Eichinger, Guo-li Ming, Jorge L. Muñoz-Jordan, Hengli Tang, Ignacio Pino, Hongjun Song, Jiang Qian and Heng Zhu
Molecular and Cellular Proteomics

Screening and validation of novel biomarkers in osteoarticular pathologies by comprehensive combination of protein array technologies
Álvaro Sierra-Sánchez, Diego Garrido-Martín, Lucía Lourido, María González-González, Paula Díez, Cristina Ruiz-Romero, Ronald Sjöber, Conrad Droste, Javier De Las Rivas, Peter Nilsson, Francisco Blanco and Manuel Fuentes
Journal of Proteome Research



"CDI Laboratories recently purchased an Arrayjet ‘Ultra Marathon II’ to print microarrays for our ‘HuProt’ product line, focussed arrays with a smaller subset of proteins for discovery arrays and hybridoma project work. CDI is planning to print monoclonal arrays and membrane protein arrays with the new technology in the near future. Arrayjet’s technology was chosen as we needed to quintuple capacity, preferably with one Instrument, its hi-tech, precise and user-friendly capabilities were an obvious benefit. One of the added advantages of the company structure is that they provide in-house printing through ‘Arrayjet Advance’ and we were able to carry out several studies over several months to reaffirm our belief that the technology would improve many facets of our operation."

Dr Ignatio Pino, CEO, CDI Laboratories, Baltimore